1. HPV Vaccine Policy Project CPCRN HPV Workgroup 2008 CPCRN National Meeting Miriam Laugesen, Ritesh Mistry, Roshan Bastani, Vicky Taylor, Jack Needleman and other interested CPCRNs

2. Background HPV vaccine is a breakthrough, but there has been much controversy –Mandating vaccines: school entry, immigration –Concerns in public health community about competing costs and impact on Pap test usage A consensus has yet to be reached about whether and how to promote the vaccine State and national policy can have important impacts on vaccine awareness and vaccine usage

4. HPV Policy Project Update First paper: –Describes quantity and variety of HPV vaccine bills across 50 states from Jan 2006 – June 2008 –Traces the introduction, enactment, and failure to enactment of HPV vaccine bills –Data have been abstracted from all bills introduced over this time period A complete draft of the paper has been written: –Submit to Health Affairs by end of December 2008 –Laugesen M, Mistry R, Carameli K, Needleman J, Bastani R.

5. Type of PolicyNumberPercent Vaccination mandate bill3026.7 Public information/education bill32.7 Insurance coverage bill2623.2 Combination bill53*47.3 Total *11 mandate bills 112100% No activity: Alaska, Arkansas, Deleware Idaho, Nebraska, New Hampshire, Wyoming

6. Enacted Bills (n=24, 26%)

7. Examples of Next Papers State level predictors of policy introduction and enactment Case study of states: –comparing mandates, no mandates –A lot of activity, no activity Impact of policies on outcomes such as knowledge / awareness, intention, uptake

8. State-Level Predictors of Policy Activity Outcomes: –Types of HPV vaccine bills introduced –Types of HPV vaccine bills enacted State-level Predictors: –Population Size –SES: per capita income –Percent Democrats in upper and lower house –Party of governor –Conservativeness: percent Christian adherents, Death penalty state –HMO penetration –Cervical cancer burden